A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

  • STATUS
    Recruiting
  • End date
    Dec 31, 2024
  • participants needed
    60
  • sponsor
    Ascentage Pharma Group Inc.
Updated on 26 March 2022

Summary

APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents, indicating that APG-1252 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is intended for the treatment of patients with neuroendocrine tumors. The purpose of the phase 1b study to establish the maximum tolerated dose (MTD), and/or recommended phase 2 dose (RP2D). Preliminary efficacy and pharmacokinetic properties will be aslo evaluated.

Details
Condition Neuroendocrine Tumors
Treatment Pelcitoclax
Clinical Study IdentifierNCT04893759
SponsorAscentage Pharma Group Inc.
Last Modified on26 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed neuroendocrine tumors (G1, G2, G3)
Locally advanced or metastatic disease for which no standard therapy is judged appropriate by the investigator
Male or non-pregnant, non-lactating female patients age ≥18 years
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1
Estimated life span ≥3 months
At least one measurable lesion by RECIST 1.1
Adequate hematologic and bone marrow functions
Adequate renal and liver function
Adequate cardiac function
Brain metastases with clinically controlled neurologic symptoms
Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug
Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures)
Willingness and ability to comply with study procedures and follow-up examination

Exclusion Criteria

Neuroendocrine carcinoma (NEC)
Received chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or any investigational therapy within 28 days prior to the first dose of study drug; received TKIs within 5 x half-time
Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to < Grade 2
Known bleeding diathesis/disorder
Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug
Have active immune thrombocytopenic purpura (ITP), active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug)
Serious gastrointestinal bleeding within 3 months
Use of therapeutic doses of anti-coagulants is excluded, along with anti-platelet agents; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are permitted
Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry
Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry
Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements
Prior treatment with Bcl-2/Bcl-xL inhibitors
Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note